Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 47.31 percent increase over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $27.626 million which beat the analyst consensus estimate of $26.965 million by 2.45 percent. This is a 56.62 percent increase over sales of $17.639 million the same period last year.